

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4843987/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interleukin-6: an emerging regulator of pathological pain. Journal of Neuroinflammation, 2016, 13, 141.	7.2	278
2	Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends in Pharmacological Sciences, 2020, 41, 531-543.	8.7	220
3	Carbon Monoxide and Its Controlled Release: Therapeutic Application, Detection, and Development of Carbon Monoxide Releasing Molecules (CORMs). Journal of Medicinal Chemistry, 2018, 61, 2611-2635.	6.4	217
4	Development and Validation of a Nomogram for Assessing Survival in Patients With COVID-19 Pneumonia. Clinical Infectious Diseases, 2021, 72, 652-660.	5.8	86
5	PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain. Current Pharmaceutical Design, 2017, 23, 1860-1868.	1.9	74
6	Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain. Redox Biology, 2018, 14, 391-397.	9.0	74
7	Role of curcumin in the management of pathological pain. Phytomedicine, 2018, 48, 129-140.	5.3	66
8	Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain. Acta Pharmacologica Sinica, 2020, 41, 1041-1048.	6.1	58
9	Berberine protects against ischemia-reperfusion injury: A review of evidence from animal models and clinical studies. Pharmacological Research, 2019, 148, 104385.	7.1	57
10	Pharmacological inhibition of the NLRP3 inï¬,ammasome as a potential target for cancer-induced bone pain. Pharmacological Research, 2019, 147, 104339.	7.1	46
11	Minocycline as a promising therapeutic strategy for chronic pain. Pharmacological Research, 2018, 134, 305-310.	7.1	44
12	Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models. Molecular Pain, 2018, 14, 174480691879323.	2.1	42
13	The Role of CXCR3 in Neurological Diseases. Current Neuropharmacology, 2019, 17, 142-150.	2.9	39
14	Cellular and Molecular Mechanisms of Calcium/Calmodulin-Dependent Protein Kinase II in Chronic Pain. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 176-183.	2.5	37
15	Targeting glia for bone cancer pain. Expert Opinion on Therapeutic Targets, 2016, 20, 1365-1374.	3.4	36
16	Motor Cortex-Periaqueductal Gray-Spinal Cord Neuronal Circuitry May Involve in Modulation of Nociception: A Virally Mediated Transsynaptic Tracing Study in Spinally Transected Transgenic Mouse Model. PLoS ONE, 2014, 9, e89486.	2.5	34
17	Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain. Current Pharmaceutical Design, 2015, 21, 5029-5033.	1.9	34
18	The Role of Spinal GABAB Receptors in Cancer-Induced Bone Pain in Rats. Journal of Pain, 2017, 18, 933-946.	1.4	33

DA-WEI YE

#	Article	IF	CITATIONS
19	The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies. , 2021, 225, 107846.		33
20	PPARÎ <sup>3</sup> activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway. Biomedicine and Pharmacotherapy, 2020, 129, 110356.	5.6	32
21	Src-family protein tyrosine kinases: A promising target for treating chronic pain. Biomedicine and Pharmacotherapy, 2020, 125, 110017.	5.6	32
22	Role of Spinal Cord in Regulating Mouse Kidney: A Virally Mediated Trans-synaptic Tracing Study. Urology, 2012, 79, 745.e1-745.e4.	1.0	29
23	STING/NF-κB/IL-6-Mediated Inflammation in Microglia Contributes to Spared Nerve Injury (SNI)-Induced Pain Initiation. Journal of NeuroImmune Pharmacology, 2022, 17, 453-469.	4.1	29
24	Stimulation of the dorsal portion of subthalamic nucleus may be a viable therapeutic approach in pharmacoresistant epilepsy: A virally mediated transsynaptic tracing study in transgenic mouse model. Epilepsy and Behavior, 2014, 31, 114-116.	1.7	22
25	β2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis. Biomedicine and Pharmacotherapy, 2021, 144, 112331.	5.6	20
26	Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 517-527.	1.6	16
27	ldentification of neuroanatomic circuits from spinal cord to stomach in mouse: retrograde transneuronal viral tracing study. International Journal of Clinical and Experimental Pathology, 2014, 7, 5343-7.	0.5	16
28	Wnt signaling: A prospective therapeutic target for chronic pain. , 2022, 231, 107984.		15
29	The endocannabinoid system: Novel targets for treating cancer induced bone pain. Biomedicine and Pharmacotherapy, 2019, 120, 109504.	5.6	13
30	Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 781820.	2.8	12
31	Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases. Current Neuropharmacology, 2022, 20, 2066-2080.	2.9	7
32	Inhibitory effects of intrathecal p38β antisense oligonucleotide on bone cancer pain in rats. International Journal of Clinical and Experimental Pathology, 2014, 7, 7690-8.	0.5	4
33	The optimal segment for spinal cord stimulation in intractable epilepsy: A virally mediated transsynaptic tracing study in spinally transected transgenic mice. Epilepsy and Behavior, 2013, 29, 599-601.	1.7	3
34	Reply to Collins et al. Clinical Infectious Diseases, 2020, 73, 558-559.	5.8	2
35	Nox2 contributes to reactive oxygen species-induced redox imbalance in cancer-induced bone pain. American Journal of Translational Research (discontinued), 2021, 13, 1269-1279.	0.0	1
36	Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies Journal of Clinical Oncology, 2016, 34, 363-363.	1.6	0

#	Article	IF	CITATIONS
37	Correlation of negative PD-L1 expression with TMB-H and MSI-H rates Journal of Clinical Oncology, 2019, 37, e13162-e13162.	1.6	0